Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC50, 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.

[1]  Kai Du,et al.  Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. , 2005, The Journal of clinical investigation.

[2]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[3]  G. Sawicki,et al.  High treatment burden in adults with cystic fibrosis: challenges to disease self-management. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  D. Clarke,et al.  Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. , 2007, The Biochemical journal.

[5]  P. Compain,et al.  Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. , 2006, Bioorganic & medicinal chemistry.

[6]  P. Zeitlin,et al.  In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. , 1997, The Journal of clinical investigation.

[7]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[8]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[9]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.

[10]  J. Riordan,et al.  The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating , 2006, The Journal of physiology.

[11]  N. Pedemonte,et al.  Influence of cell background on pharmacological rescue of mutant CFTR. , 2010, American journal of physiology. Cell physiology.

[12]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[13]  Alan S. Verkman,et al.  Chloride channels as drug targets , 2009, Nature Reviews Drug Discovery.

[14]  D. Perlmutter,et al.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[16]  P. Davis,et al.  Cystic fibrosis: a review of epidemiology and pathobiology. , 2007, Clinics in chest medicine.

[17]  D. Clarke,et al.  Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. , 2005, Molecular pharmaceutics.

[18]  S Grinstein,et al.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.

[19]  Jason C. Young,et al.  Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane , 2010, Science.

[20]  C. Penland,et al.  A pipeline of therapies for cystic fibrosis. , 2009, Seminars in respiratory and critical care medicine.

[21]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[22]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[23]  Y. Kuryshev,et al.  HERG channel trafficking. , 2005, Novartis Foundation symposium.

[24]  John R Yates,et al.  Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.

[25]  L. Limbird,et al.  The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. , 2001, Molecular pharmacology.

[26]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .

[27]  P. Picotti,et al.  Probing protein structure by limited proteolysis. , 2004, Acta biochimica Polonica.

[28]  M. Wilke,et al.  Parallel Improvement of Sodium and Chloride Transport Defects by Miglustat (n-Butyldeoxynojyrimicin) in Cystic Fibrosis Epithelial Cells , 2008, Journal of Pharmacology and Experimental Therapeutics.

[29]  Chad A Brautigam,et al.  Side chain and backbone contributions of Phe508 to CFTR folding , 2005, Nature Structural &Molecular Biology.

[30]  K D Wittrup,et al.  Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control* , 1998, The Journal of Biological Chemistry.

[31]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[32]  C. Sanders,et al.  Destabilizing mutations promote membrane protein misfolding. , 2004, Biochemistry.

[33]  P. Quinton.  Cystic fibrosis: lessons from the sweat gland. , 2007, Physiology.

[34]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[35]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[36]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[37]  G. Lukács,et al.  Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. , 1998, Nature structural biology.

[38]  R. Crystal,et al.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , 1991, Nature.

[39]  Adrian W. R. Serohijos,et al.  Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function , 2008, Proceedings of the National Academy of Sciences.

[40]  R. Boucher.  Cystic fibrosis: a disease of vulnerability to airway surface dehydration. , 2007, Trends in molecular medicine.

[41]  P. Pedersen,et al.  Altered protein folding may be the molecular basis of most cases of cystic fibrosis , 1992, FEBS letters.

[42]  M. Welsh,et al.  Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia , 1992, The Journal of cell biology.

[43]  J. Clancy,et al.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. , 2007, Proceedings of the American Thoracic Society.

[44]  Andrei Aleksandrov,et al.  Domain interdependence in the biosynthetic assembly of CFTR. , 2007, Journal of molecular biology.

[45]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.